Drug Profile

BRL 303

Alternative Names: BRL-303

Latest Information Update: 10 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BRL Medicine
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Aug 2023 Discontinued - Preclinical for Prostate cancer in China (Parenteral) (BRL Medicine pipeline, August 2023)
10 Aug 2023 Preclinical trials in Autoimmune disorders in China (Parenteral) (BRL Medicine pipeline, August 2023)
15 Jul 2022 Preclinical trials in Multiple myeloma in China (Parenteral) before July 2022 (BRL Medicine pipeline, July 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com